Завершено
Фаза III
Беларусь
BIBW 2992 (афатиниб) · Boehringer Ingelheim Pharma GmbH & Co. KG
LUX-Breast 1; An Open Label, Randomised Phase III Trial of BIBW 2992 and Vinorelbine Versus Trastuzumab and Vinorelbine in Patients With Metastatic HER2-overexpressing Breast Cancer Failing One Prior Trastuzumab Treatment